In a chat with WINA's Rob Schilling, IPI's Dr. Merrill Matthews discusses the two-fold blow as a result of Pfizer halting work developing new drugs for Alzheimer’s disease and Parkinson’s disease, causing not just a disappointment to those waiting for a cure, but pushing up the costs of other drugs.
2018 01 12 schilling show matthews prescription drug costs